FGF-P Peptide Analog for Acute Radiation Syndrome Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current agents for mitigating acute radiation syndrome (ARS) are inadequate, particularly for gastrointestinal syndrome (AGS), which is a major component of ARS, as they either lack desirable properties or are not effective in increasing survival time and modifying the lethal dose of GI injury.
Innovation Solution
Development of a novel polypeptide analog, FGF-P (CYRSRKYSSWYVALKRC), which acts as a fibroblast growth factor (FGF) analog, capable of promoting angiogenesis, stimulating stem cell proliferation, and enhancing survival by administering an effective amount of the peptide to prevent or treat disorders affecting rapidly proliferating tissues, including AGS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native FGFs are used as radiation protectors, then they can protect the small bowel and reduce deaths from AGS, but they lack desirable properties such as stability and enzyme resistance
Solution Approach 1:
The patent modifies the amino acid sequence of native FGFs to create analogs with improved stability and enzyme resistance while maintaining biological activity. Specific changes include substituting amino acids at critical positions to resist proteolytic degradation and enhance half-life, directly addressing the contradiction between efficacy and stability.
Solution Approach 2:
The invention creates composite peptide structures that combine the protective properties of FGFs with enhanced stability features. The peptide analogs integrate multiple functional domains that provide both radioprotection and resistance to enzymatic degradation, resolving the contradiction between biological activity and compositional stability.
2Stability of the object's composition
If FGF analogs are developed with improved stability, then they may have extended half-life, but their ability to bind to FGF receptors and stimulate proliferation may be compromised
Solution Approach 1:
The patent applies local modifications to specific regions of the FGF peptide sequence. Critical receptor-binding domains are preserved with high affinity, while other regions are modified to enhance stability and enzyme resistance. This localized approach allows simultaneous optimization of binding affinity and stability without compromising either function.
Solution Approach 2:
The FGF peptide is divided into functional segments: a stable core region that provides structural integrity and enzyme resistance, and a reactive region that maintains high-affinity receptor binding. This segmentation allows each region to be optimized independently for its specific function, resolving the contradiction between stability and binding affinity.
3Reliability
If FGF analogs are used to treat AGS, then survival rates increase, but the cost of production and administration may be high
Solution Approach 1:
The patent creates peptide analogs that are synthesized through efficient chemical methods and can be administered as short-acting therapeutic agents. The peptides are designed to be produced at scalable costs and provide sufficient therapeutic effect during the critical window for AGS treatment, addressing the contradiction between survival benefit and production cost.
Data Source
Figure 1A~1B
Figure 2A~2D
Figure 3~4
AI summary
The invention relates to novel peptide comprising FGF-P and methods of use thereof.